spacer
home > white papers > Contemporary Issues in Comparator Trial Supply - Clinigen CTS
WHITE PAPERS
logo_Clinigen_C.JPG

Clinigen CTS

phone +44 (0)1283 495 010
email ctsinquiries@clinigengroup.com
web http://www.clinigengroup.com/clinical-trial-services
email Pitcairn House, Crown Square, First Avenue Burton-on-Trent, Staffordshire, DE14 2WW UK

Contemporary Issues in Comparator Trial Supply

The past five years has seen a great deal of change in clinical trial management. As the bio-pharma industry looks to speed development times and consolidate new product pipelines, in a quest for improved R&D efficiency, it is no surprise that phase III trial design, planning and execution in particular has been under great scrutiny. Cost of comparator agents alone has escalated to up to $100m per year for top companies (and is predicted to grow further). Consequently innovative approaches, novel project planning and increasingly close partnerships with specialist outsourcing service providers have come to the fore.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>


White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement